A Phase 2 interventional study of Eltrombopag 12.5 mg and Eltrombopag 25 mg in Cytopaenia, sponsored by Novartis Pharmaceuticals. Completed at 12 sites in Japan. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2019-05-03.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing eltrombopag in Anemia, Aplastic — 3 open to participants now, 3 under way, 1 of them phase 3. eltrombopag · Anemia, Aplastic.
Among the 17 studies testing eltrombopag in Anemia, Aplastic, this one is the 11th largest by enrollment, is the only one that started in 2014, is one of 11 in phase 2, and was the 6th registered.
372 studies on the registry are indexed under Anemia, Aplastic; 99 are open to participants now.
Browse Anemia, Aplastic studies →3 of the 17 studies testing eltrombopag in Anemia, Aplastic are open now, in 2 countries. Recruiting first, the newest first:
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 3–99
Melbourne Health · Sites in Australia
Ages 18+
Assiut University
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 59 Anemia, Aplastic studies recruiting now, 21 (36%) set no upper age limit and 30 (51%) stop at 75 or younger; 38 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 14 · Phase 3 4
First in 2009; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 21 is below the median of 37 across 281 interventional studies indexed under Anemia, Aplastic.
Median enrollment 36 across the 17 interventional studies. Of the 13 that completed or were terminated, 11 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 17 have an industry lead sponsor. The 8 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
14 studies in Anemia, Aplastic by Novartis: 1 open now, 1 under way, none of them phase 3. Of 12 finished, 7 (58%) have results posted.
Among the 14 studies in Anemia, Aplastic by Novartis, this one is one of 2 that started in 2014, is one of 7 in phase 2, and was the 4th registered.
Novartis’s Anemia, Aplastic studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing eltrombopag in Anemia, Aplastic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 14 in Anemia, Aplastic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a non-randomized, open-label, phase II study to assess the efficacy and safety of eltrombopag in Japanese moderate or more severe aplastic anemia (AA) subjects with a platelet count \<30,000/microliter who were refractory to anti-thymocyte globulin (ATG)-based immunosuppressive therapy (IST), who have relapsed after ATG-based IST, or who are ineligible for ATG-based IST.
Eltrombopag was expected to improve trilineage blood cells and decrease transfusion frequency based on the result from the previous study in patients with severe AA. This study used the hematologic response rate, defined as the proportion of subjects showing improvement in at least one of the three blood cell lineages or a decrease in blood transfusion volume, as the primary endpoint.
A total of 36 subjects were screened and 21 were enrolled in the study. Treatment with eltrombopag started at 25 milligram (mg)/day and increased by 25 mg/day every 2 weeks according to the platelet count up to 100 mg/day. Response assessment was performed at 3 months after starting the study treatment (Week 13). Subjects in whom the treatment was assessed as effective continued with the study treatment. Subjects in whom the treatment was assessed as effective (when meeting any of the response criteria) at 6 months after starting the study treatment (Week 26) might enter the extension phase and continue the treatment with eltrombopag. The primary endpoint was the hematologic response rate at Week26.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects were assigned the investigational product (eltrombopag 25 mg/day) orally once a day under fasting condition. The dose adjustment was done every 2 weeks according to the platelet count (increased by eltrombopag 25 mg/day every 2 weeks according to the platelet count up to 100 mg/day).
Drug: Eltrombopag 12.5 mg · Drug: Eltrombopag 25 mg
White, round, film-coated tablets containing 12.5 mg of eltrombopag free acid (SB-497115-GR, eltrombopag) in each tablet
Also known as: Revolade
White, round, film-coated tablets containing 25 mg of eltrombopag free acid (SB-497115-GR, eltrombopag) in each tablet
Also known as: Revolade
Hematological Response at Week 26
Hematologic response rate at 6 months (at WeeK 26) after the start of study treatment was defined as the percentage of subjects who met any of the response criteria (Platelet count, Hemoglobin level, Neutrophil count). 1 ) Platelet count: an increase from baseline by 20,000/μL or more (In the absence of platelet transfusion), or no platelet transfusion requirements for 8 weeks; 2) Hemoglobin: When the baseline hemoglobin level is \<9 g/dL: Without RBC transfusion at baseline, an increase from baseline by 1.5 g/dL or more; With RBC transfusion at baseline, a decrease of at least 4 units in RBC transfusions in the post-treatment 8-week period compared to the pre-treatment 8-week period (1 unit = RBC derived from 200 mL blood); 3) Neutrophil count: an increase from baseline by 500/μL or more (in the absence of granulocyte colony-stimulating factor (G-CSF)), or (if \< 500/μL at baseline) an increase by 100 % or more. Only descriptive analysis done.
Time frame: D183 (Week 26)
Change in Platelet Count From Baseline in the Absence of Platelet Transfusion Over Time
The changes in observed values for Platelet Count were summarized. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done.
Time frame: Up to 2.5 years
Change in Hemoglobin From Baseline in the Absence of Red Blood Cell (RBC) Transfusion Over Time
The changes in observed values for Hemoglobin were summarized. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done.
Time frame: Up to 2.5 years
Change in Neutrophil Count From Baseline in the Absence of Granulocyte-colony Stimulating Factor (G-CSF) Over Time
The changes in observed values for Neutrophil Count were summarized. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done.
Time frame: Up to 2.5 years
Hematological Response at Week 13 in Terms of the Platelet Count, Hemoglobin Level and Neutrophil Count
The frequency and percentage were calculated with 95% confidence interval (CI) of responses (which meet each response criteria) of platelet count, hemoglobin and neutrophil count at Week 13.
Time frame: Week 13
Duration of Hematological Response in Participants Who Responded at the Week 13
The duration of haematological response was defined, for subjects who responded at the Week 13 visit, as the number of months from the first date of a response until the first date of a relapse or the date the subject was last assessed. Only subjects with at least 2 response assessments were included in the duration of response assessment. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done.
Time frame: Up to 2.5 years
Volume of (Platelet and RBC) Transfusion in Each Period
The amount of blood transfusion (platelets, RBC) were summarized. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done.
Time frame: Day 1, Day 92 (Week 13), Day 183 (Week 26), Extension W39 and Extension W52
Frequency of (Platelet and RBC) Transfusion in Each Period
The frequency of blood transfusion (platelets, RBC) were summarized. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done.
Time frame: Day 1, Day 92 (Week 13), Day 183 (Week 26), Extension W39 and Extension W52
Percentage of Participants With Reduced Volume of Transfusion (Platelet and RBC)
The proportion of the participants for whom the amount of blood transfusion (platelets and RBC) is decreased was measured and reported as a percentage. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done. This analysis was performed for the subjects who were baseline transfusion dependent.
Time frame: Up to 2.5 years
Percentage of Participants Who Become Transfusion (Platelet and RBC) Independent
The proportion of participants for whom blood transfusion (platelets and RBC) became unnecessary was measured and reported as a percentage. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done. This analysis was performed for the subjects who were baseline transfusion dependent.
Time frame: Up to 2.5 years
Long-term Safety and Tolerability of Eltrombopag
The frequency and percentage of subjects who experienced adverse events (AEs), serious adverse events (SAEs) and deaths by primary system organ class (SOC) and MedDRA preferred term were summarized.
Time frame: Up to 30 days after last dose of study treatment
Number of Participants With Bleeding Events and Severity of Bleeding
The measurements were followed up to Week 26 and thereafter in the extension part.
Time frame: Up to 30 days after last dose of study treatment
Maximum Observed Plasma Concentration (Cmax) for Eltrombopag
At some study sites, full blood sampling for pharmacokinetic (PK) evaluation of Eltrombopag was performed on Day 14 to calculate Cmax, tmax, AUC(0-t), and AUC(0-tau). PK parameters were calculated from plasma concentration-time data using non-compartmental methods.
Time frame: Day 14 at 25 mg QD (-0.05, 0.15, 0.30, 0.45, 1.00, 1.30 and 24.00), at 50,75 and 100 mg QD (pre-dose)
Time to Reach the Maximum Plasma Concentration (Tmax) for Eltrombopag
At some study sites, full blood sampling for pharmacokinetic (PK) evaluation of Eltrombopag was performed on Day 14 to calculate Cmax, tmax, AUC(0-t), and AUC(0-tau). PK parameters were calculated from plasma concentration-time data using non-compartmental methods.
Time frame: Day 14 at 25 mg QD (-0.05, 0.15, 0.30, 0.45, 1.00, 1.30 and 24.00), at 50,75 and 100 mg QD (pre-dose)
Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Subject Across All Treatments (AUC 0-t) and Over the Dosing Interval (AUC 0-tau) for Eltrombopag
At some study sites, full blood sampling for pharmacokinetic (PK) evaluation of Eltrombopag was performed on Day 14 to calculate Cmax, tmax, AUC(0-t), and AUC(0-tau). PK parameters were calculated from plasma concentration-time data using non-compartmental methods.
Time frame: Day 14 at 25 mg QD (-0.05, 0.15, 0.30, 0.45, 1.00, 1.30 and 24.00), at 50,75 and 100 mg QD (pre-dose)
Mean Change in Eltrombopag Concentration in Pharmacokinetic Serum Samples Over Time at Days 14 and 15
At every study center, blood samples was be collected on Day 15 of multiple doses of eltrombopag 25 mg to determine the plasma eltrombopag concentration prior to the next dose (trough concentration). In addition, one-point pre-dose blood sampling was performed at every study center on Day 15 of multiple doses of eltrombopag 50 mg, 75 mg and 100 mg to determine trough concentrations. PK parameters were calculated from plasma concentration-time data using non-compartmental methods.
Time frame: Day 14 (pre-dose, 1, 2, 4, 6, 8 and 24 post-dose), Day 15 (pre-dose)
The study took place in 12 clinical sites in Japan
| Milestone | Eltrombopag |
|---|---|
| Started | 21 |
| Safety set (ss) | 21 |
| Pharmacokinetic analysis set (pas) | 21 |
| Completed | 16 |
| Not completed | 5 |
| Withdrew: Investigator discretion | 1 |
| Withdrew: Lack of efficacy | 1 |
| Withdrew: Protocol deviation | 1 |
| Withdrew: Protocol-defined stopping criteria | 2 |
Hematologic response rate at 6 months (at WeeK 26) after the start of study treatment was defined as the percentage of subjects who met any of the response criteria (Platelet count, Hemoglobin level, Neutrophil count). 1 ) Platelet count: an increase from baseline by 20,000/μL or more (In the absence of platelet transfusion), or no platelet transfusion requirements for 8 weeks; 2) Hemoglobin: When the baseline hemoglobin level is \<9 g/dL: Without RBC transfusion at baseline, an increase from baseline by 1.5 g/dL or more; With RBC transfusion at baseline, a decrease of at least 4 units in RBC transfusions in the post-treatment 8-week period compared to the pre-treatment 8-week period (1 unit = RBC derived from 200 mL blood); 3) Neutrophil count: an increase from baseline by 500/μL or more (in the absence of granulocyte colony-stimulating factor (G-CSF)), or (if \< 500/μL at baseline) an increase by 100 % or more. Only descriptive analysis done.
| Percentage of participants | Eltrombopag |
|---|---|
| Hematological Response at Week 26 | 47.6 (25.7 to 70.2) |
The changes in observed values for Platelet Count were summarized. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done.
| Giga/Liter (Gi/L) | Eltrombopag |
|---|---|
| Baseline | 12.19 ± 7.155 |
| D92 Week13 | 6.32 ± 7.698 |
| D183 Week26 | 13.09 ± 14.015 |
| Extension W39 | 23.50 ± 22.037 |
| Extension W52 | 21.50 ± 15.720 |
| Extension W78 | 36.69 ± 23.798 |
| Extension W104 | 35.79 ± 21.389 |
| Extension W130 | 42.79 ± 28.795 |
| Extension W156 | 25.50 ± NA |
| Withdrawal | 8.81 ± 19.387 |
| Last Assessment On-Therapy | 18.38 ± 24.017 |
The changes in observed values for Hemoglobin were summarized. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done.
| Gram/Liter (g/L) | Eltrombopag |
|---|---|
| Baseline | 70.4 ± 13.95 |
| D92 Week13 | 4.9 ± 11.91 |
| D183 Week26 | 8.8 ± 17.08 |
| Extension W39 | 19.3 ± 22.29 |
| Extension W52 | 24.0 ± 21.11 |
| Extension W78 | 32.8 ± 19.58 |
| Extension W104 | 34.4 ± 20.44 |
| Extension W130 | 31.6 ± 16.99 |
| Extension W156 | 16.0 ± NA |
| Withdrawal | -3.0 ± 13.85 |
| Last Assessment On-Therapy | 10.0 ± 20.14 |
The changes in observed values for Neutrophil Count were summarized. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done.
| Giga/Liter (Gi/L) | Eltrombopag |
|---|---|
| Baseline | 0.8247 ± 0.47985 |
| D92 Week13 | 0.3321 ± 0.51398 |
| D183 Week26 | 0.2046 ± 0.43640 |
| Extension W39 | 0.4537 ± 0.87231 |
| Extension W52 | 0.5236 ± 0.58529 |
| Extension W78 | 0.8579 ± 0.62320 |
| Extension W104 | 0.6312 ± 1.05205 |
| Extension W130 | 1.1835 ± 1.97999 |
| Extension W156 | -0.1712 ± NA |
| Withdrawal | 0.3246 ± 0.72222 |
| Last Assessment On-Therapy | 0.4307 ± 1.22084 |
The frequency and percentage were calculated with 95% confidence interval (CI) of responses (which meet each response criteria) of platelet count, hemoglobin and neutrophil count at Week 13.
| Percentage of participants | Eltrombopag |
|---|---|
| Hematological Response at Week 13 in Terms of the Platelet Count, Hemoglobin Level and Neutrophil Count | 61.9 (38.4 to 81.9) |
The duration of haematological response was defined, for subjects who responded at the Week 13 visit, as the number of months from the first date of a response until the first date of a relapse or the date the subject was last assessed. Only subjects with at least 2 response assessments were included in the duration of response assessment. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done.
| Months | Eltrombopag |
|---|---|
| Hematological Response | 10.68 (1.64 to 28.32) |
| Platelet/Platelet Transfusion | 32.62 (32.62 to 32.62) |
| Hemoglobin/RBC Transfusion Response | 19.19 (5.54 to 28.37) |
| Neutrophils Response | 3.02 (1.64 to 4.63) |
The amount of blood transfusion (platelets, RBC) were summarized. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done.
| milliliter (mL) | Eltrombopag |
|---|---|
| Day 1 (Platelets) | 600.0 ± 309.84 |
| Day 1 (RBC) | 1663.2 ± 1083.31 |
| Day 92 (Week 13) (Platelets) | 400.0 ± 438.18 |
| Day 92 (Week 13) (RBC) | 1152.9 ± 978.59 |
| Day 183 (Week 26) (Platelets) | 280.0 ± 389.87 |
| Day 183 (Week 26) (RBC) | 800.0 ± 1131.37 |
| Extension W39 (Platelets) | 0.0 ± 0.00 |
| Extension W39 (RBC) | 300.0 ± 848.53 |
| Extension W52 (Platelets) | 0.0 ± 0.00 |
| Extension W52 (RBC) | 400.0 ± 1131.37 |
The frequency of blood transfusion (platelets, RBC) were summarized. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done.
| Tansfusion | Eltrombopag |
|---|---|
| Day 1 (Platelets) | 3.0 ± 1.55 |
| Day 1 (RBC) | 4.1 ± 2.51 |
| Day 92 (Week 13) (Platelets) | 2.0 ± 2.19 |
| Day 92 (Week 13) (RBC) | 2.9 ± 2.41 |
| Day 183 (Week 26) (Platelets) | 1.4 ± 1.95 |
| Day 183 (Week 26) (RBC) | 1.9 ± 2.64 |
| Extension W39 (Platelets) | 0.0 ± 0.00 |
| Extension W39 (RBC) | 0.8 ± 2.12 |
| Extension W52 (Platelets) | 0.0 ± 0.00 |
| Extension W52 (RBC) | 0.9 ± 2.47 |
The proportion of the participants for whom the amount of blood transfusion (platelets and RBC) is decreased was measured and reported as a percentage. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done. This analysis was performed for the subjects who were baseline transfusion dependent.
| Percentage of participants | Eltrombopag |
|---|---|
| Platelet Transfusion Decrease | 83.3 |
| RBC Transfusion Decrease | 73.7 |
The proportion of participants for whom blood transfusion (platelets and RBC) became unnecessary was measured and reported as a percentage. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done. This analysis was performed for the subjects who were baseline transfusion dependent.
| Percentage of participants | Eltrombopag |
|---|---|
| Platelet Transfusion Independence | 66.7 |
| RBC Transfusion Independence | 47.4 |
The frequency and percentage of subjects who experienced adverse events (AEs), serious adverse events (SAEs) and deaths by primary system organ class (SOC) and MedDRA preferred term were summarized.
| Percentage of participants | Eltrombopag |
|---|---|
| AEs by Primary SOC (SOC) | 100 |
| Grade 1 AEs by Primary SOC (SOC) | 85.7 |
| Grade 2 AEs by Primary SOC (SOC) | 81.0 |
| Grade 3 AEs by Primary SOC (SOC) | 42.9 |
| Grade 4 AEs by Primary SOC (SOC) | 4.8 |
| SAEs by Primary System Organ Class (SOC) | 28.6 |
The measurements were followed up to Week 26 and thereafter in the extension part.
| N° of Participants with Bleeding events | Eltrombopag |
|---|---|
| AE Bleeding - On Treatment | 11 |
| Grade 1 AE Bleeding - On Treatment | 9 |
| Grade 2 AE Bleeding - On Treatment | 2 |
| AE Bleeding - Followup Phase | 6 |
| Grade 1 AE Bleeding - Followup Phase | 5 |
| Grade 2 AE Bleeding - Followup Phase | 1 |
| SAE Bleeding - On Treatment | 0 |
| SAE Bleeding - Followup Phase | 3 |
| Grade 1 SAE Bleeding - Followup Phase | 2 |
| Grade 2 SAE Bleeding - Followup Phase | 1 |
At some study sites, full blood sampling for pharmacokinetic (PK) evaluation of Eltrombopag was performed on Day 14 to calculate Cmax, tmax, AUC(0-t), and AUC(0-tau). PK parameters were calculated from plasma concentration-time data using non-compartmental methods.
| nanogram per milliliter (ng/mL) | Eltrombopag |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) for Eltrombopag | 6410 ± 4200 |
At some study sites, full blood sampling for pharmacokinetic (PK) evaluation of Eltrombopag was performed on Day 14 to calculate Cmax, tmax, AUC(0-t), and AUC(0-tau). PK parameters were calculated from plasma concentration-time data using non-compartmental methods.
| Hour | Eltrombopag |
|---|---|
| Time to Reach the Maximum Plasma Concentration (Tmax) for Eltrombopag | 2.00 (1.90 to 7.58) |
At some study sites, full blood sampling for pharmacokinetic (PK) evaluation of Eltrombopag was performed on Day 14 to calculate Cmax, tmax, AUC(0-t), and AUC(0-tau). PK parameters were calculated from plasma concentration-time data using non-compartmental methods.
| Hours*nanograms/milliliter (hr*ng/mL) | Eltrombopag |
|---|---|
| AUC(0-t) | 123000 ± 92900 |
| AUC(0-tau) | 99200 ± 119000 |
At every study center, blood samples was be collected on Day 15 of multiple doses of eltrombopag 25 mg to determine the plasma eltrombopag concentration prior to the next dose (trough concentration). In addition, one-point pre-dose blood sampling was performed at every study center on Day 15 of multiple doses of eltrombopag 50 mg, 75 mg and 100 mg to determine trough concentrations. PK parameters were calculated from plasma concentration-time data using non-compartmental methods.
| nanogram per milliliter (ng/mL) | Eltrombopag |
|---|---|
| Eltrombopag 25 mg (Day 14) - 0Hr | 4530 ± 3870 |
| Eltrombopag 25 mg (Day 14) - 1Hr | 5240 ± 3740 |
| Eltrombopag 25 mg (Day 14) - 2Hr | 5980 ± 3990 |
| Eltrombopag 25 mg (Day 14) - 4Hr | 5870 ± 3870 |
| Eltrombopag 25 mg (Day 14) - 6Hr | 5720 ± 4130 |
| Eltrombopag 25 mg (Day 14) - 8Hr | 5430 ± 4170 |
| Eltrombopag 25 mg (Day 14) - 24Hr | 4390 ± 3680 |
| Eltrombopag 25 mg (Day 15) - 0Hr | 3730 ± 2430 |
| Eltrombopag 50 mg (Day 15) - 0Hr | 8530 ± 6410 |
| Eltrombopag 75 mg (Day 15) - 0Hr | 15200 ± 12000 |
| Eltrombopag 100 mg (Day 15) - 0Hr | 19300 ± 15000 |
Collected over Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit up to approximately 3 years and 1 month.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eltrombopag | 0/21 (0%) | 6/21 (28.6%) | 20/21 (95.2%) |
| Event | Eltrombopag |
|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 2/21 |
| Retinal detachmentEye disorders | 1/21 |
| Abdominal painGastrointestinal disorders | 1/21 |
| EnterocolitisGastrointestinal disorders | 1/21 |
| Hepatic function abnormalHepatobiliary disorders | 1/21 |
| Fibrin D dimer increasedInvestigations | 1/21 |
| Back painMusculoskeletal and connective tissue disorders | 1/21 |
| Spinal osteoarthritisMusculoskeletal and connective tissue disorders | 1/21 |
| Event | Eltrombopag |
|---|---|
| NasopharyngitisInfections and infestations | 8/21 |
| Abdominal pain upperGastrointestinal disorders | 4/21 |
| Hepatic function abnormalHepatobiliary disorders | 4/21 |
| PyrexiaGeneral disorders | 3/21 |
| GastroenteritisInfections and infestations | 3/21 |
| UrticariaSkin and subcutaneous tissue disorders | 3/21 |
| HypertensionVascular disorders | 3/21 |
| DiarrhoeaGastrointestinal disorders | 2/21 |
| DyspepsiaGastrointestinal disorders | 2/21 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 2/21 |
| Age, Continuous(Years) | Eltrombopag |
|---|---|
| Median | 53.0 (19 to 79) |
| Sex: Female, Male(Participants) | Eltrombopag |
|---|---|
| Female | 12 |
| Male | 9 |
| Race (NIH/OMB)(Participants) | Eltrombopag |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 21 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
Ran from Jul 2014 to primary completion in Sep 2015, 13 months.
Results were first posted in May 2019, 3 years 7 months after primary completion.
Of 60 phase 2 interventional studies under Anemia, Aplastic, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 104. This study's 13 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eltrombopag